Name

Will Therapeutics

Legal name

Will Therapeutics Inc.

Website

https://willtherapeutics.com

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

Eating Disorder Treatment Programs (HLAFACAK)

Keywords

• Small molecule therapeutics
• Compulsive disorder treatment
• Central nervous system drugs
• Anorexia nervosa therapy
• Acetylcholinesterase inhibitors

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotech company developing a novel therapeutic compound for anorexia nervosa and related compulsive disorders. Revenue model not yet established as the company is in pre-clinical/early clinical stage of drug development.

Core offering

Will Therapeutics develops a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug designed to restore dopamine balance in the striatum neural pathway that drives compulsive behavior. The lead program targets anorexia nervosa as the initial indication, with pipeline expansion planned into obsessive compulsive disorder, addiction disorders, tics/Tourette's, body-focused repetitive behaviors, and other eating disorders.

Product overview

Will Therapeutics is a biopharmaceutical company developing a single core therapeutic compound—a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug. The company focuses on treating anorexia nervosa as its initial indication, with pipeline opportunities for obsessive compulsive disorder, phone/social media addiction, gambling addiction, tics/Tourette's, body-focused repetitive behaviors (BFRBs), rigid behaviors in autism, and other eating disorders. The compound is designed to restore dopamine balance in the striatum, a neural pathway central to habit and compulsion, representing a targeted biological approach rather than behavioral management.

Differentiator

Problem solved

Functional benefit

Products and services

• Brain-Penetrant Acetylcholinesterase Inhibitor Protodrug

Quantifiable outcome

• 0 approved drugs for anorexia nervosa vs 15 approved for cervical cancer with similar mortality
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Quebec Consortium for Drug DiscoverycoreStrategic or Co-development PartnerResearch grant awarded by the Quebec Consortium for Drug Discovery supporting the company's translational science program combining preclinical validation, human signal, and molecular redesign for the treatment of compulsive disorders.

Recent moves5 records

Expansion highlights4 records

Direct peers

• COMPASS Pathways: Clinical-stage CNS biotech developing therapies for psychiatric conditions; comparable as a small-molecule/circuit-targeted biotech addressing high-need psychiatric indications where few treatment options exist.
• Sage Therapeutics: CNS-focused biopharma pioneering targeted neuromodulators for serious psychiatric and neurological disorders, including Zurzuvae; closely comparable in modality and stage of CNS drug development.
• Axsome Therapeutics: Commercial-stage CNS biopharma with Auvelity and other CNS therapeutics in psychiatry; relevant as a small-molecule CNS commercializer advancing therapies for underserved psychiatric conditions.
• Karuna Therapeutics: Developed xanomeline-based therapies for schizophrenia and related conditions, illustrating a precedent of circuit-driven CNS small molecules advancing in psychiatric indications; structurally similar biotech archetype.
• Neumora Therapeutics: Clinical-stage neuroscience company developing brain-targeted therapies for neuropsychiatric and neurodegenerative conditions; analogous as a biology-driven, CNS-focused private biotech.
• Cerevel Therapeutics: Neuroscience biopharma developing precision small molecules for CNS disorders; directly comparable as a circuit-targeted, brain-penetrant small-molecule CNS developer.

Emerging players

• Biohaven Pharmaceuticals: Neuroscience-focused biopharmaceutical company with a portfolio of CGRP-targeting and other neurology/psychiatry assets; comparable as a CNS specialty player pursuing differentiated mechanisms for serious brain disorders.

Broad incumbents

• Intra-Cellular Therapies: CNS-focused biopharma with Caplyta approved for schizophrenia and bipolar depression; comparable as an established specialty CNS developer with multiple psychiatric indications.
• Acadia Pharmaceuticals: Established CNS biopharma commercializing therapies for neuropsychiatric conditions such as Parkinson's psychosis and Rett syndrome; a broader incumbent in the same specialty prescription CNS space.
• Denali Therapeutics: Biopharmaceutical company specializing in engineering brain-penetrant therapeutics, including enzyme inhibitors for CNS disorders; directly comparable on brain-targeted delivery platform and neurodegeneration/neuropsychiatry focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Will Therapeutics